BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2093-2099

  Robinson, Brett S ^a   Riccardi, Keith A ^a   Gong, Yi Fei ^a   Guo, Qi ^a   Stock, David A ^a   Blair, Wade S ^a   Terry, Brian J ^a   Deminie, Carol A ^a   Djang, Fred ^a   Colonno, Richard J ^a   Lin, Pin Fang ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEIN PRECURSOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIMICROBIAL THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

BLOOD PROTEINS; CELLS, CULTURED; DRUG COMBINATIONS; DRUG INTERACTIONS; GENE PRODUCTS, GAG; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; PROTEIN PRECURSORS; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0033931167     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2093-2099.2000     Document Type: Article

References (43)

1. Bechtold, C. M., A. K. Patick, M. Alam, J. Greytok, J. A. Tino, P. Chen, E. Gordon, S. Ahmad, J. C. Barish, R. Zahler, P.-F. Lin, and R. Colonno. 1995. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and Prt. Antimicrob. Agents Chemother. 39:374-379.
2. Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. 1996. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1491-1497.
3. Boden, D., and M. Markowitz. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:2775-2783.
4. Bryant, M., D. Getman, M. Smidt, J. Marr, M. Clare, R. Dillard, D. Lansky, G. DeCrescenzo, R. Heintz, K. Houseman, K. Reed, J. Stolzenbach, J. Talley, M. Vazquez, and R. Mueller. 1995. SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 39:2229-2234.
5. Cameron, D. W., A. J. Japour, Y. Xu, A. Hsu, J. Mellors, C. Farthing, C. Cohen, D. Poretz, M. Markowitz, S. Follansbee, J. B. Angel, D. McMahon, D. Ho, V. Devanarayan, R. Rode, M. Salgo, D. J. Kempf, R. Granneman, J. M. Leonard, and E. Sun. 1999. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13:213-224.
6. Chong, K.-T., and P. J. Pagano. 1997. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother. 41:2367-2373.
7. Chou, T.-C, and P. Talalay. 1984. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
8. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Grahman, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodarkewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
9. Daluge, S. A., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
10. Deminie, C., C. M. Bechtold, D. Stock, M. Alam, F. Djang, A. H. Balch, T.-C. Chou, M. Prichard, R. J. Colonno, and P.-F. Lin. 1996. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob. Agents Chemother. 40:1346-1351.
11. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41:1099-1107.
12. Flexner, D. 1998. HIV-protease inhibitors. Drug Ther. 338:1281-1292.
13. Gulick, R. M. 1997. Current antiretroviral therapy: an overview. Quality Life Res. 6:471-474.
14. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
15. Hubert, J. J. 1992. Bioassay. Kendall/Hunt Publishing Co., Dubuque, Iowa.
16. Ido, E., H, Han, F. J. Kezdy, and J. Tang. 1991. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J. Biol. Chem. 266:24359-24366.
17. Johnson, V. A., and R. E. Byington. 1990. Infectivity assay (virus yield assay), p. 71-76. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research. Stockton Press, New York, N.Y.
18. Kageyama, S., B. D. Anderson, B. L. Hoesterey, H. Hayashi, Y. Kiso, K. P. Flora, and H. Mitsuya. 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38:1107-1111.
19. Kalish, V., S. Kaldor, B. Shetty, J. Tatlock, J. Davies, M. Hammond, B. Dressman, J. Fritz, K. Appelt, S. Reich, L. Musick, B. Wu, and K. Su. 1995. Iterative protein structure-based drug design and synthesis of HIV protease inhibitors. Eur. J. Med. Chem. 30:202S-214S.
20. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X.-P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl. Acad. Sci. USA 92:2484-2488.
21. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
22. Keppel, G. 1982. Design and analysis: a researchers handbook, 2nd ed. Prentice-Hall, Inc., Englewood Cliffs, N.J.
23. Kohl, N. E., R. E. Diehl, E. Rands, L. J. Davis, M. G. Hanobik, B. Wolanski, and R. A. Dixon. 1991. Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. J. Virol. 65:3007-3014.
24. Kramer, R. A., M. D. Schaber, A. M. Skalka, K. Ganguly, F. Wong-Staal, and E. P. Reddy. 1986. HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 231:1580-1584.
25. Kuritzkes, D. R. 1997. HIV resistance to current therapies. Antiviral Ther. 2:61-67.
26. Lin, P. F., H. Samanta, R. E. Rose, A. K. Patick, J. Trimble, C. M. Bechtold, D. R. Revie, C. K. Narayan, M. E. Federici, H. Li, A. Lee, R. E. Anderson, and R. J. Colonno. 1994. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170:1157-1164.
27. Lin, Y., X. Lin, L. Hong, S. Foundling, R. L. Heinrikson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B. M. Dunn, and J. Tang. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry 34:1143-1152.
28. Livingston, D. J., S. Pazhanisamy, D. J. T. Porter, J. A. Partaledis, R. D. Tung, and G. R. Painter. 1998. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172:1238-1245.
29. Matayoshi, E. D., G. T. Wang, G. A. Krafft, and J. Erickson. 1990. Novel fluorogenic substrates for assaying retroviral protease by resonance energy transfer. Science 247:954-958.
30. Molla, A., G. R. Granneman, E. Sun, and D. J. Kempf. 1998. Recent developments in HIV protease inhibitor therapy. Antiviral Res. 39:1-23.
31. Morris-Jones, S., G. Moyle, and P. J. Easterbrook. 1997. Antiretroviral therapies in HIV-1 infection. Expert Opin. Investig. Drugs 6:1049-1061.
32. Murphy, R. L., R. M. Gulick, V. DeGruttola, R. T. D'Aquila, J. J. Eron, J. P. Sommadossi, J. S. Currier, L. Smeaton, I. Frank, A. M. Caliendo, J. G. Gerber, R. Tung, and D. R. Kuritzkes. 1999. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infections. AIDS Clinical Trials Group 347 Study Team. J. Infect. Dis. 179:808-816.
33. Patick, A. K., T. J. Boritzki, and L. A. Bloom. 1997. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 41:2159-2164.
34. Pettit, S. C., S. F. Michael, and R. Swanstrom. 1993. The specificity of the HIV-1 protease. Perspect. Drug Discov. Des. 1:69-83.
35. Potts, B. J. 1990. "Mini" reverse transcriptase (RT) assay, p. 103-106. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research, Stockton Press, New York, N.Y.
36. Prichard, M. N., K. R. Aseltine, and C. Shipman, Jr. 1992. MacSynergy II version 1.0 user's manual. University of Michigan. Ann Arbor, Mich.
37. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
38. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, R. W. Lambert, J. H. Merrett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
39. St. Clair, M. H. S., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. M. Sadler, M. R. Blum, and G. Painter. 1996. In vitro activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 29:53-56.
40. Vacca, J. P., and J. H. Condra. 1997. Clinically effective HIV-1 protease inhibitors. Drug Discov. Today 2:261-272.
41. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
42. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
43. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. O'Brien, R. G. Ball, S. K. Balani, J. H. Lin, I.-W. Chen, W. A. Schleif, V. V. Sardana, W. J. Long, V. W. Byrnes, and E. A. Emini. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605.